The Evolution of Benzothiazepine Therapeutics: A Comprehensive History of Diltiazem

The pharmacological development of diltiazem hydrochloride represents a seminal transition in cardiovascular medicine, marking the emergence of the benzothiazepine class as a distinct therapeutic entity. While the mid-twentieth century was characterized by a burgeoning understanding of calcium’s role in muscular contraction, the realization of diltiazem as a clinical tool required the convergence of Japanese chemical innovation, American entrepreneurial licensing strategies, and a global evolution in drug delivery technology. This report examines the exhaustive trajectory of diltiazem, from its 17th-century corporate roots in Osaka to its current standing as a foundational agent in the 2023 and 2024 clinical guidelines for atrial fibrillation and hypertension.

The Ancestral and Corporate Origins of Tanabe Seiyaku

The history of diltiazem is inextricably linked to the history of Tanabe Seiyaku Co., Ltd., one of the oldest pharmaceutical concerns in the world. The corporate lineage traces back to 1604, when Tanabeya Matazaemon initiated overseas trade, importing medicinal materials to Japan.¹ By 1678, Tanabeya Gohei I established a store in Tosabori, Osaka, manufacturing and selling “Tanabeya medicine,” a compound that would eventually receive honorary recognition from the Imperial Household.¹ The relocation of the business to Doshomachi, the traditional center of Japan’s medicine trade, in 1791, solidified the company’s influence within the Yakushu Nakagai Kabu Nakama, or the Medicine Traders Guild.¹

As the 20th century progressed, Tanabe Seiyaku transitioned from traditional remedies to modern industrial pharmacology. The establishment of the Honjo Kawasaki-cho factory in 1916 and the subsequent success with products such as NIPPAS, an anti-tuberculosis agent launched in 1950, set the stage for the company’s entry into specialized cardiovascular research.¹ By the late 1960s, the focus of the global pharmaceutical community had shifted toward the physiology of the “slow channel,” a term popularized by Albrecht Fleckenstein to describe the inward calcium current in cardiac and vascular tissues.²

The discovery of diltiazem occurred within this high-stakes environment of international competition to identify non-toxic calcium antagonists. Japanese researchers, led by H. Kugita, H. Inoue, and Taku Nagao, began exploring novel 1,5-benzothiazepine derivatives, a structural class that was largely unexplored for cardiovascular applications.³ The initial chemical synthesis of diltiazem was documented in German patent DE 1805714 and U.S. patent 3,562,257, filed between 1969 and 1971.³ These foundational patents described the coronary vasodilating properties of the compound, which was codenamed CRD-401 during its early investigational phases.³

Chemical Synthesis and the Resolution of Stereocenters

The chemical identity of diltiazem is defined as 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate.⁵ Structurally, it is characterized by a seven-membered thiazepine ring fused to a benzene ring, forming the 1,5-benzothiazepine core. A critical aspect of diltiazem’s efficacy lies in its stereochemistry; the molecule possesses two chiral centers at the C-2 and C-3 positions of the thiazepine ring.³

In the early 1970s, the research team at Tanabe Seiyaku determined that the therapeutic activity resided primarily in the (+)-cis isomer, which corresponds to the (2S, 3S) configuration.³ The resolution of these optical isomers was published by H. Inoue et al. in 1973 in the journal Yakugaku Zasshi.³ Later, during the 1980s, Shionogi researchers developed even more refined stereospecific synthesis methods to ensure high-purity yields of the (2S, 3S) enantiomer.³

The synthesis involves a multi-step pathway, starting with the nucleophilic addition of 4-aminophenol to 2-chloro-N,N-dimethylethylamine to generate key intermediates.⁷ Following oxidation—often facilitated by agents such as [bis(trifluoroacetoxy)iodo]benzene—the process proceeds through a Michael addition with 3-mercaptopropionic acid and a subsequent cyclization using coupling reagents like N,N’-dicyclohexylcarbodiimide.⁷ This precise construction of the benzothiazepine core was essential because alternative isomers, such as the trans-isomers or the (-)-enantiomers, lacked the specific binding affinity for the L-type calcium channel required for clinical effect.⁶

Property	Value and Specification
Molecular Formula	(Base)
Molecular Formula (HCl)
Molecular Weight	(Base); (HCl)
CAS Registry Number	(Base); (HCl)
Specific Rotation ()	(c = 1.002 in methanol)
Melting Point	to
Dissociation Constant ()	(calculated)

The physical properties of diltiazem hydrochloride reflect its suitability for pharmaceutical formulation. It appears as fine needles or a white crystalline powder with a characteristically bitter taste and no discernible odor.³ Its high solubility in water, methanol, and chloroform facilitates rapid absorption from the gastrointestinal tract, though this very solubility necessitated the development of controlled-release technologies to overcome its high clearance rate.⁵

Molecular Pharmacology and Pore-Blocking Mechanisms

The mechanism of action of diltiazem is fundamentally different from the dihydropyridine class (such as nifedipine) and shows nuanced differences from the phenylalkylamine class (such as verapamil).⁵ Diltiazem is a potent inhibitor of the L-type voltage-gated calcium channel ( 1.2), which is the primary mediator of calcium entry into cardiac and vascular smooth muscle during depolarization.²

Atomic Basis of Channel Blockade

The structural basis for diltiazem’s action was elucidated through X-ray crystallographic analysis of ancestral calcium channel constructs, such as .¹² Research confirms that diltiazem binds within the central cavity of the calcium channel, positioned directly underneath the ion selectivity filter.¹² This binding physically obstructs the passage of ions through the pore. The diltiazem receptor site is complex; it overlaps significantly with the site for phenylalkylamines but remains distinct from the dihydropyridine site.¹²

A significant finding in diltiazem pharmacology is its allosteric relationship with other drugs. For instance, the presence of amlodipine (a dihydropyridine) alters the binding pose of diltiazem.¹² Under the influence of dihydropyridines, the diltiazem molecule can adopt a high-affinity configuration induced by voltage-dependent inactivation.¹² In this pose, the tertiary amino group of diltiazem projects upward, interacting with ion coordination sites (specifically Site 3) formed by the backbone carbonyls of the channel protein.¹² This structural insight explains the synergistic cardiovascular effects and the pharmacokinetic interactions often observed when diltiazem is co-administered with other calcium channel blockers.¹²

Hemodynamic and Electrophysiological Profiles

Diltiazem exhibits an “intermediate” specificity that historically placed it between the highly vascular-selective dihydropyridines and the highly cardio-selective verapamil.⁵ Its physiological effects can be categorized into three primary domains:

1. Vascular Effects: Diltiazem induces significant relaxation of vascular smooth muscle, primarily in the arterial bed. This results in decreased peripheral vascular resistance and a reduction in both systolic and diastolic blood pressure.⁵ Critically, diltiazem is a potent dilator of both epicardial and subendocardial coronary arteries.¹⁹
2. Cardiac Electrophysiology: As a Class IV antiarrhythmic, diltiazem targets the sinoatrial (SA) and atrioventricular (AV) nodes.³ It slows the firing rate of the SA node (negative chronotropy) and prolongs the conduction time through the AV node (negative dromotropy).¹⁴
3. Myocardial Contractility: Diltiazem possesses a negative inotropic effect, meaning it reduces the force of muscular contraction. However, in humans with normal ventricular function, this effect is often offset by the reduction in afterload.¹¹

The clinical utility of diltiazem arises from this balanced profile. Unlike nifedipine, it does not typically provoke reflex tachycardia because its direct inhibitory effect on the SA node counteracts the sympathetic response to vasodilation.¹⁸ Conversely, its negative inotropic effect is significantly less aggressive than that of verapamil, making it a safer alternative for certain patients with modest cardiac impairment, although it remains contraindicated in severe heart failure.²⁰

The Marion Laboratories Licensing Breakthrough

The global expansion of diltiazem owes much to the unconventional business strategy of Ewing M. Kauffman, the founder of Marion Laboratories.²⁷ Established in 1950 in Kauffman’s Kansas City home, Marion Laboratories avoided the exorbitant costs of original R&D.²⁷ Instead, Kauffman focused on licensing “orphan” or promising compounds from international markets that lacked a strong presence in the United States.²⁷

In the late 1970s, Marion Laboratories identified Tanabe Seiyaku’s diltiazem as a potential blockbuster for the management of angina pectoris. Marion secured the North American licensing rights and initiated the clinical program necessary for FDA approval.²⁷ The success of this partnership transformed Marion Laboratories from a small operation selling oyster-shell calcium supplements into a major pharmaceutical player.²⁷ By 1984, the two companies entered into a formal joint venture to manufacture and market Tanabe’s pipeline products across the U.S. and Canada.²⁷

The marketing of diltiazem under the brand name Cardizem utilized Marion’s robust sales force, which was renowned for its aggressive and effective physician outreach.²⁸ This commercial infrastructure was a critical factor in the 1989 merger between Marion Laboratories and Merrell Dow Pharmaceuticals, creating Marion Merrell Dow (MMD).²⁸ Merrell Dow brought a rich heritage of research (and a history fraught with the thalidomide and clomifene eras), which combined with Marion’s sales expertise to create a dominant force in the cardiovascular market.²⁸

Pivotal Clinical Trials and FDA Approval Milestones

The regulatory journey of diltiazem in the United States was marked by a series of high-impact clinical trials that validated its use for increasingly broad indications.

1982: The Initial Approval for Angina

Diltiazem was first approved by the FDA in 1982 for the management of chronic stable angina and vasospastic (Prinzmetal’s) angina.⁵ The pivotal cooperative clinical trial, often cited as Strauss et al. (1982), evaluated 63 patients in a multicenter, double-blind protocol.³¹ This study demonstrated that diltiazem achieved a significantly greater reduction in anginal attack frequency and nitroglycerin consumption compared to placebo.³¹ Furthermore, diltiazem increased total exercise duration on treadmill tests, establishing its role in improving the quality of life for ischemic heart disease patients.²²

For vasospastic angina, diltiazem proved particularly effective. It was shown to inhibit ergonovine-induced coronary artery spasm, a key diagnostic hallmark of the condition.¹¹ Trials involving patients with rest angina following myocardial infarction demonstrated that diltiazem could completely suppress cyclic ST-segment elevation.³⁴ A 44-week prospective randomized crossover trial involving 16 patients with documented variant angina showed a 73% to 80% decrease in anginal frequency compared to placebo, with minimal adverse effects.³⁵

1991: Expansion to Supraventricular Tachyarrhythmias

While the oral form was establishing itself in the angina market, research into parenteral diltiazem was progressing. In October 1991, the FDA approved Cardizem injectable (intravenous diltiazem) for the temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter and for the rapid conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.³⁷

The electrophysiological basis for this approval was diltiazem’s ability to prolong the AH conduction time and the effective refractory period of the AV node by approximately 20%.¹¹ In acute settings, an initial IV bolus of was shown to be highly effective, with repeat doses of providing a cumulative effective ratio of up to 94% for rate control.²⁰

1992: The Hypertension Indication and Sustained Release

The final major regulatory hurdle was the approval for hypertension. While diltiazem was known to have antihypertensive properties, the need for three-to-four-times-daily dosing with the immediate-release (IR) tablets was a significant barrier to the chronic management of high blood pressure.⁴¹

The approval of Cardizem SR (sustained release) and subsequently Cardizem CD (controlled delivery) in the early 1990s revolutionized the treatment landscape. In 1992, diltiazem was officially approved for the treatment of hypertension in the U.S..²⁹ Double-blind, dose-response studies showed that once-daily diltiazem lowered diastolic blood pressure in a linear manner over a range of 90 mg to 540 mg.²¹

The “Calcium Channel Blocker Wars” of the 1980s

As diltiazem entered the market, it competed directly with verapamil (Calan/Isoptin) and nifedipine (Adalat/Procardia) in what was colloquially known as the “calcium channel blocker wars”.¹⁸ This era was defined by intense marketing and a rapid succession of clinical trials aimed at differentiating these heterogeneous drugs.¹⁴

Differentiation Through Hemodynamics

Nifedipine was marketed as the potent vasodilator, ideal for severe hypertension but often limited by its propensity to cause peripheral edema and reflex tachycardia.¹⁴ Verapamil was the drug for arrhythmias but was hampered by a high incidence of constipation (occurring significantly more often than with diltiazem) and its strong negative inotropic potential.¹⁴

Diltiazem was positioned as the “safe middle ground.” It provided significant coronary vasodilation—comparable to nifedipine in many models—but with the added benefit of heart rate control.¹⁷ In conscious dog studies, for instance, nifedipine accelerated heart rate, while verapamil slowed it; diltiazem, however, had little to no effect on the resting inotropic state while still providing effective vasodilation.¹⁸ This unique profile allowed Marion Merrell Dow to capture a massive share of the market; by 1986, Cardizem accounted for 47% of Marion’s net sales.²⁷

The Controversy and Outcome Studies

The mid-1990s saw a “calcium-channel blocker controversy” triggered by reports of potential adverse events and a lack of data on long-term clinical outcomes.⁴⁶ Critics argued that the reliance on surrogate endpoints (like blood pressure reduction) was insufficient.⁴⁶ This led to massive, long-term trials like the Nordic Diltiazem (NORDIL) study and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).¹⁷

The NORDIL study was particularly significant for diltiazem; it demonstrated that diltiazem-based therapy was as effective as conventional therapy (beta-blockers and diuretics) in preventing cardiovascular morbidity and mortality.¹⁷ Notably, diltiazem showed a 25% reduction in fatal and non-fatal stroke compared to the conventional treatment groups.¹⁷ These findings solidified diltiazem’s place as a first-line or second-line option in global hypertension guidelines.¹⁷

Technological Mastery: From Microbeads to Geomatrix

The pharmacokinetic challenges of diltiazem necessitated some of the most advanced pharmaceutical engineering of the late 20th century. With a plasma half-life of only 3 to 4.5 hours and an absolute bioavailability of approximately 40% due to extensive first-pass metabolism, the IR tablet was suboptimal for long-term use.¹⁰

The Dual Microbead System (Cardizem CD)

Cardizem CD was engineered as a once-a-day extended-release capsule.²³ Its internal architecture consisted of a “dual microbead” system. These microbeads were enclosed in a capsule, but each had a different thickness of copolymer coating.⁴⁸

• Rapid-release beads: These were thin-coated and designed to release 40% of the total diltiazem content within the first 12 hours of the dosing interval.⁴⁸
• Delayed-release beads: These had a thicker coating and released the remaining 60% of the drug during the subsequent 12 hours.⁴⁸

This design produced two peaks on the concentration-time curve, which theoretically provided more consistent therapeutic levels and allowed for “trough” measurements that reflected true efficacy at the end of the 24-hour period.²³

Graded Extended-Release (Cardizem LA)

Launched in the early 2000s, Cardizem LA (long-acting) utilized a different technology known as the “graded extended-release system” or “Geomatrix”.¹⁰ Unlike the capsule-based CD, Cardizem LA was a tablet formulation engineered to provide a smoother drug-release profile, resulting in a single peak plasma concentration.⁴⁸

The innovation of Cardizem LA was its focus on chronotherapeutics.⁴⁹ Because cardiovascular events like myocardial infarction and stroke peak in the morning hours (the “morning surge”), Cardizem LA was designed to be dosed in the evening (typically at 10:00 PM).⁴⁹ This bedtime dosing resulted in significantly greater bioavailability during the critical 6:00 AM to 12:00 PM window compared to morning dosing.⁴⁹ In clinical trials, evening-dosed Cardizem LA was shown to be superior to amlodipine in controlling the early morning blood pressure surge in African American hypertensive patients.⁴⁹

Formulation	Delivery Mechanism	Dosing Frequency	Peak Plasma Time (Tmax​)
IR Tablet	Compressed matrix	TID or QID	to hours
Cardizem SR	Single-bead system	BID	to hours
Cardizem CD	Dual microbead	Once Daily	to hours
Cardizem LA	Graded-release tablet	Once Daily	to hours

Corporate Consolidation and the Sanofi-Biovail Nexus

The ownership history of the Cardizem brand mirrors the complex M&A activity of the pharmaceutical industry at the turn of the millennium.

The Rise and Fall of Hoechst Marion Roussel

Following the formation of Marion Merrell Dow, the company became a target for European firms looking to expand their U.S. footprint. In 1995, the German corporation Hoechst AG acquired MMD to form Hoechst Marion Roussel (HMR).⁵⁰ This merger created the second-largest pharmaceutical company in the world at the time.⁵² However, the merger was complicated by antitrust issues; Hoechst was already developing Tiazac (another once-daily diltiazem) with Biovail Corporation.⁵¹ The FTC mandated that Hoechst return the rights to Tiazac to Biovail to ensure continued competition in the diltiazem market.⁵¹

The Aventis and Sanofi Mergers

In 1999, HMR merged with Rhône-Poulenc to form Aventis.⁵⁰ Aventis inherited the Cardizem franchise, but the drug was facing mounting generic pressure.⁴² In 2004, Sanofi-Synthélabo acquired Aventis in a hostile takeover to form Sanofi-Aventis.⁵⁰ Through these mergers, the diltiazem portfolio passed through several of the largest corporate entities in history, eventually becoming part of the Sanofi global product line.⁵⁰

Biovail’s Strategic Acquisition

Recognizing that the Cardizem brand still held significant value, the Canadian firm Biovail Corporation—which had originally been a competitor through Tiazac—acquired the North American rights to the entire Cardizem line from Aventis in 2001 for $409.5 million.⁵⁴ This move allowed Biovail to transition from a generic manufacturer to a specialty brand company. Biovail developed Cardizem LA and Cardizem XL (a generic line extension) to extend the patent life of the diltiazem franchise.⁵⁴ Biovail eventually merged with Valeant Pharmaceuticals in 2010, and Valeant was later renamed Bausch Health, which currently maintains the Cardizem trademark.⁵⁶

Legal Conflict and the “Pay-for-Delay” Controversy

The history of diltiazem is also a landmark case in pharmaceutical antitrust law. As the patent for Cardizem CD approached its expiration in the late 1990s, Hoechst Marion Roussel (HMRI) engaged in a series of legal maneuvers to preserve its monopoly.

The Andrx Agreement

On September 24, 1997, HMRI entered into a “Stipulation and Agreement” with Andrx Pharmaceuticals, the first company to gain preliminary FDA approval for a generic version of Cardizem CD.⁵⁹ Under this agreement, HMRI paid Andrx nearly $90 million to keep its generic product (Cartia XT) off the market for nearly a year.⁶⁰ Because Andrx held the “first-to-file” 180-day exclusivity period, its decision not to market its generic effectively blocked all other generic competitors from entering the market as well.⁶⁰

This “pay-for-delay” scheme became the subject of intense litigation by the FTC and various U.S. states.⁶⁰ The legal fallout resulted in hundreds of millions of dollars in settlements and served as a catalyst for federal efforts to reform the Hatch-Waxman Act to prevent similar abuses of the generic exclusivity period.⁶⁰

Diltiazem in the 21st Century: Guidelines and Future Outlook

Despite being decades old, diltiazem remains a cornerstone of cardiovascular therapy. Its inclusion in the most recent clinical guidelines demonstrates its enduring clinical relevance.

2023 ACC/AHA Atrial Fibrillation Guidelines

The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation” classifies AF as a progressive disease and emphasizes the importance of rate control.⁶² Diltiazem is designated as a Class 1 recommendation for rate control in patients with AF or atrial flutter, provided they do not have heart failure with reduced ejection fraction (HFrEF).⁶²

The guidelines establish four stages of AF:

• Stage 1: At risk for AF.
• Stage 2: Pre-AF.
• Stage 3: AF (including 3A: paroxysmal, 3B: persistent, 3C: long-standing persistent).
• Stage 4: Permanent AF.⁶⁴

Diltiazem is used across these stages for symptom management. However, the 2023 update reinforces the absolute contraindication of diltiazem in HFrEF (Stage C and D), as its negative inotropic effects increase the risk of heart failure exacerbations.²⁴ In patients with preserved ejection fraction (HFpEF), diltiazem remains a vital tool for heart rate management, especially during exercise.²⁰

ANOCA and Emerging Indications

Modern research into Angina and Non-Obstructive Coronary Artery disease (ANOCA) has brought diltiazem back into the investigational spotlight. The EDIT-CMD randomized clinical trial (2022) evaluated diltiazem’s effect on coronary microvascular dysfunction.⁶⁶ While the study found that 360 mg/day of diltiazem did not normalize all microvascular parameters, it significantly reduced the prevalence of epicardial spasm.⁶⁶ This suggests that diltiazem remains the gold-standard treatment for patients whose angina is driven by vasomotor dysfunction rather than obstructive atherosclerosis.¹⁹

Off-Label and Specialized Uses

Over the decades, diltiazem has found utility beyond the heart. It is frequently prescribed off-label for:

• Migraine Prophylaxis: As a second-line preventative agent.⁵
• Chronic Anal Fissures: Compounded as a 2% topical gel to reduce internal anal sphincter pressure.⁵
• Raynaud’s Phenomenon: To reduce the frequency and severity of vasospastic attacks in the extremities.⁴⁴
• Pulmonary Hypertension: Particularly in “vasoreactive” patients during diagnostic testing.⁵

Pharmacokinetic Summary and Metabolic Fate

Diltiazem’s efficacy is heavily dependent on its metabolic profile. It is a substrate and a potent inhibitor of the CYP3A4 isoenzyme, which leads to significant drug-drug interactions.⁵

Metabolism and Excretion

Diltiazem undergoes extensive hepatic metabolism, primarily through deacetylation, N-demethylation, and O-demethylation.³ Its primary metabolite, desacetyl diltiazem, is present in the plasma at levels of 10% to 20% of the parent drug and retains about 25% to 50% of diltiazem’s coronary vasodilating activity.¹⁰

• Absorption: Rapid and near-complete (), but bioavailability is reduced to 40% due to first-pass effects.⁹
• Protein Binding: 70% to 80%, primarily to albumin.¹⁰
• Elimination: Only 2% to 4% of diltiazem is excreted unchanged in the urine; the rest is eliminated as metabolites through both renal and biliary routes.¹⁰

In patients with hepatic cirrhosis, the half-life of diltiazem increases significantly, and bioavailability can increase by up to 69%, necessitating careful dose titration.¹¹ Conversely, renal impairment has shown no significant effect on the pharmacokinetic profile of the drug.¹⁰

Conclusion: The Enduring Legacy of the 1,5-Benzothiazepines

The history of diltiazem is a narrative of chemical elegance and pharmaceutical persistence. From its origins in the early patents of Tanabe Seiyaku to the high-stakes “pay-for-delay” legal battles of the generic era, diltiazem has navigated the complexities of the global pharmaceutical market to remain a vital clinical agent. Its unique “intermediate” hemodynamic profile, combining heart rate control with potent vasodilation, has ensured its place in the 2023 and 2024 cardiovascular guidelines, nearly half a century after its initial synthesis. As research into microvascular dysfunction and chronotherapeutics continues to evolve, the legacy of diltiazem remains firmly rooted in the intersection of tradition and innovation..¹

Works cited

1. Tanabe Pharma Historical Museum,     , https://shiryokan.tanabe-pharma.com/sp/en/history/
2. EFFECT OF DILTIAZEM ON ELECTRICAL AND MECHANICAL ACTIVITY OF ISOLATED CARDIAC VENTRICULAR MUSCLE OF GUINEA PIG – j-stage,     , https://www.jstage.jst.go.jp/article/jphs1951/25/4/25_4_383/_article
3. Diltiazem,     , https://www.drugfuture.com/chemdata/diltiazem.html
4. Development of diltiazem, a calcium antagonist: coronary vasodilating and antihypertensive actions – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/7074990/
5. Diltiazem | C22H26N2O4S | CID 39186 – PubChem – NIH,     , https://pubchem.ncbi.nlm.nih.gov/compound/Diltiazem
6. (PDF) Asymmetric syntheses of (+)-diltiazem hydrochloride – ResearchGate,     , https://www.researchgate.net/publication/240939623_Asymmetric_syntheses_of_-diltiazem_hydrochloride
7. Innovative Synthesis of Diltiazem/Clentiazem Analogs – Southern Adventist University,     , https://knowledge.e.southern.edu/cgi/viewcontent.cgi?article=1036&context=jiur
8. Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/18754582/
9. Study Details | NCT04777045 | Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial | ClinicalTrials.gov,     , https://clinicaltrials.gov/study/NCT04777045
10. Cardizem LA (diltiazem hydrochloride) tablet label – accessdata.fda.gov,     , https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021392s014lbl.pdf
11. Reference ID: 2868026 – accessdata.fda.gov,     , https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018602s063lbl.pdf
12. Structural Basis for Diltiazem Block of a Voltage-Gated Ca2+ Channel – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/31391290/
13. Calcium Channel Blockers – StatPearls – NCBI Bookshelf,     , https://www.ncbi.nlm.nih.gov/books/NBK482473/
14. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.,     , https://www.merckmillipore.com/DO/en/tech-docs/paper/684935
15. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/8675249/
16. Comparison of Nifedipine Alone and With Diltiazem or Verapamil in Hypertension,     , https://www.ahajournals.org/doi/10.1161/01.HYP.28.1.109
17. Diltiazem | C22H26N2O4S | CID 39186 – PubChem,     , https://pubchem.ncbi.nlm.nih.gov/compound/Diltiazem#section=Pharmacology-and-Properties
18. Differential cardiovascular effects of calcium channel blocking agents: potential mechanisms – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/6277175/
19. Diltiazem – Wikipedia,     , https://en.wikipedia.org/wiki/Diltiazem
20. Diltiazem – StatPearls – NCBI Bookshelf – NIH,     , https://www.ncbi.nlm.nih.gov/books/NBK532937/
21. 020062Orig1s042.pdf – accessdata.fda.gov,     , https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020062Orig1s042.pdf
22. and long-term efficacy of high-dose oral diltiazem for angina due to coronary artery disease – American Heart Association Journals,     , https://www.ahajournals.org/doi/pdf/10.1161/01.cir.68.1.139
23. Cardizem CD: Package Insert / Prescribing Information – Drugs.com,     , https://www.drugs.com/pro/cardizem-cd.html
24. Verapamil Versus Diltiazem – Clinical Comparison – Med Ed 101,     , https://www.meded101.com/verapamil-versus-diltiazem-clinical-comparison/
25. Comparative effects of verapamil, diltiazem, and nifedipine on hemodynamics and left ventricular function during acute myocardial ischemia in dogs – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/6690104/
26. Calcium Channel Blockers: Verapamil & Diltiazem – Picmonic,     , https://www.picmonic.com/pathways/nursing/courses/standard/pharmacological-nursing-324/antiarrhythmics-1472/calcium-channel-blockers-verapamil-and-diltiazem_1656
27. Marion Laboratories, Inc. | Encyclopedia.com,     , https://www.encyclopedia.com/books/politics-and-business-magazines/marion-laboratories-inc
28. Marion Merrell Dow – Wikipedia,     , https://en.wikipedia.org/wiki/Marion_Merrell_Dow
29. History of Marion Merrell Dow, Inc. – FundingUniverse,     , https://www.fundinguniverse.com/company-histories/marion-merrell-dow-inc-history/
30. Reference ID: 3720012 This label may not be the latest approved by FDA. For current labeling information, please visit https://,     , https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021392s019lbl.pdf
31. Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: report of a cooperative clinical trial – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/7036709/
32. Diltiazem: 20 Years’ experience in cardiovascular medicine – PMC,     , https://pmc.ncbi.nlm.nih.gov/articles/PMC6654284/
33. Efficacy and safety of sustained-release diltiazem in stable angina pectoris – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/3510525/
34. Effect of diltiazem on recurrent spontaneous angina after acute myocardial infarction,     , https://pubmed.ncbi.nlm.nih.gov/6831648/
35. Long-term efficacy of diltiazem for control of symptoms of coronary artery spasm – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/6339105/
36. Efficacy of diltiazem for coronary artery spasm – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/3904332/
37. cardizem monovial – accessdata.fda.gov,     , https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020792ap.pdf
38. APPLICATION NUMBER: – 215252Orig1s000 OTHER REVIEW(S) – accessdata.fda.gov,     , https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215252Orig1s000OtherR.pdf
39. NDA 21-392/S-010 Page 3 CARDIZEM LA (Diltiazem Hydrochloride) Extended Release Tablets Rx only Once-a-Day Dosage LB0024-06 Re – accessdata.fda.gov,     , https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021392s010lbl.pdf
40. Assessment of the efficacy, optimal dosage, and safety of diltiazem in early treatment of unstable angina pectoris – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/16075828/
41. Diltiazem (Cardizem): Uses, Side Effects, Interactions & More – GoodRx,     , https://www.goodrx.com/diltiazem/what-is
42. MYLAN RECEIVES TENTATIVE APPROVAL FOR FIRST GENERIC CARDIZEM (DILTIAZEM) – Citeline News & Insights,     , https://insights.citeline.com/PS020600/MYLAN-RECEIVES-TENTATIVE-APPROVAL-FOR-FIRST-GENERIC-CARDIZEM-DILTIAZEM/
43. Controlled Release Technologies for Diltiazem Hydrochloride: A Comprehensive Review of Solid Dosage Innovations – PMC,     , https://pmc.ncbi.nlm.nih.gov/articles/PMC12655500/
44. Calcium channel blockers in emergency medicine – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/6380352/
45. Discovery and Development of Calcium Channel Blockers – PMC,     , https://pmc.ncbi.nlm.nih.gov/articles/PMC5447095/
46. The calcium-channel blocker controversy: historical perspective and important lessons for future pharmacotherapies. An international society of pharmacoepidemiology ‘hot topic’ – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/19025799/
47. Cardizem LA – accessdata.fda.gov,     , https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021392_S002_CARDIZEM_LA_EXENTED_AP.pdf
48. Cardizem CD Versus LA – What’s The Difference? – Med Ed 101,     , https://www.meded101.com/cardizem-cd-versus-la-whats-the-difference/
49. Diltiazem hydrochloride: New technologies and evolution of …,     , https://pmc.ncbi.nlm.nih.gov/articles/PMC6654580/
50. Sanofi – Wikipedia,     , https://en.wikipedia.org/wiki/Sanofi
51. Hoechst AG | Federal Trade Commission,     , https://www.ftc.gov/news-events/news/press-releases/1995/09/hoechst-ag
52. Roussel Uclaf – Wikipedia,     , https://en.wikipedia.org/wiki/Roussel_Uclaf
53. Investors – Sanofi,     , https://www.sanofi.com/en/india/investors
54. Biovail spends $409.5-million on cardiovascular drug product line | CBC News,     , https://www.cbc.ca/news/business/biovail-spends-409-5-million-on-cardiovascular-drug-product-line-1.261584
55. First Quarter Report,     , http://media.corporate-ir.net/media_files/NYS/BVF/reports/BVF_Q1052901.pdf
56. Cardizem La patent expiration – Pharsight,     , https://pharsight.greyb.com/drug/cardizem-la-patent-expiration
57. Alembic Pharmaceuticals announces USFDA Final Approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg – FirstWord Pharma,     , https://firstwordpharma.com/story/5911187
58. Bausch Health – Wikipedia,     , https://en.wikipedia.org/wiki/Bausch_Health
59. STATE OF NEW YORK, ex rel.,     , https://www.naag.org/wp-content/uploads/2021/10/240-2001.05.14-Multistate-Aventis-Cardizem-Complaint.pdf
60. IN THE UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION IN RE: CARDIZEM CD ANTITRUST ) MASTER FILE NO,     , https://www.naag.org/wp-content/uploads/2020/10/186.civil_.cardizem-2nd-amended-complaint-3.PDF
61. in re: cardizem cd antitrust litigation – New York State Attorney General,     , https://ag.ny.gov/sites/default/files/court-filings/2001-09-24_Second_Amended_Complaint.PDF
62. New recommendations for rhythm control—What has changed in the 2023 ACC/AHA/ACCP/HRS and 2024 ESC guidelines for atrial fibrillation, and where does dronedarone fit in? – PMC,     , https://pmc.ncbi.nlm.nih.gov/articles/PMC12811750/
63. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation – American Heart Association Journals,     , https://www.ahajournals.org/doi/10.1161/CIR.0000000000001193
64. 2023 Guideline for Diagnosis and Management of Atrial Fibrillation: Key Perspectives,     , https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2023/11/27/19/46/2023-acc-guideline-for-af-gl-af
65. Guideline Essentials: AHA Clinical Slide Series: 2023 ACC/AHA/ACCP/HRS – Professional Heart Daily,     , https://professional.heart.org/-/media/phd-files-2/science-news/clinical-slide-series/2023-atrial-fibrillation-guideline-clinical-slides.pdf
66. Efficacy of Diltiazem to Improve Coronary Vasomotor Dysfunction in ANOCA: The EDIT-CMD Randomized Clinical Trial – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/35466050/
67. Differential effects of nifedipine, verapamil, and diltiazem on noradrenaline-induced contractions, adrenergic transmitter release, and alpha-adrenoceptor binding in the female rabbit urethra – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/6147759/
68. Short-Acting Nifedipine and Diltiazem Do Not Reduce the Incidence of Cardiac Events in Patients With Healed Myocardial Infarction – American Heart Association Journals,     , https://www.ahajournals.org/doi/10.1161/01.cir.95.10.2368
69. Metoprolol vs. Diltiazem in Patients with Angina and Non-Obstructive Coronary Artery Disease with or Without Evidence of Coronary Microvascular Spasm on Acetylcholine Testing – MDPI,     , https://www.mdpi.com/2077-0383/14/21/7635
70. Federal Register, Volume 59 Issue 216 (Wednesday, November 9, 1994) – GovInfo,     , https://www.govinfo.gov/content/pkg/FR-1994-11-09/html/94-27771.htm
71. 1 INDICATIONS AND USAGE 1.1 Hypertension – accessdata.fda.gov,     , https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021392025s028lbl.pdf
72. Generic Cardizem CD Availability & Release Date – Drugs.com,     , https://www.drugs.com/availability/generic-cardizem-cd.html
73. Generic DILTIAZEM HYDROCHLORIDE INN equivalents, drug patent expiration information and freedom to operate – DrugPatentWatch,     , https://www.drugpatentwatch.com/p/generic/diltiazem+hydrochloride
74. Diltiazem Hydrochloride patent expiration – Pharsight,     , https://pharsight.greyb.com/drug/diltiazem-hydrochloride-patent-expiration
75. Diltiazem Hydrochloride Extended-Release Capsules – accessdata.fda.gov,     , https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/212317Orig1s000ltr.pdf
76. Zydus receives US FDA final approval for diltiazem hydrochloride tablets USP,     , https://www.pharmabiz.com/NewsDetails.aspx?aid=180640&sid=2
77. Eugia Pharma Receives USFDA Approval for Diltiazem Hydrochloride Injection, 25 mg/5 mL (5 mg/mL), 50 mg/10 mL (5 mg/mL), and 125 mg/25 mL (5 mg/mL), Single-Dose Vials | Eugia US,     , https://eugiaus.com/news/eugia-pharma-receives-usfda-approval-for-diltiazem-hydrochloride-injection-25-mg-5-ml-5-mg-ml-50-mg-10-ml-5-mg-ml-and-125-mg-25-ml-5-mg-ml-single-dose-vials/
78. Study Details | NCT03472495 | Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial | ClinicalTrials.gov,     , https://clinicaltrials.gov/study/NCT03472495
79. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation – Heart Rhythm Society,     , https://www.hrsonline.org/resource/2023-accahaaccphrs-guideline-diagnosis-and-management-patients-atrial-fibrillation/
80. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation – American Heart Association Journals,     , https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001193
81. Cardizem CD vs Cardizem SR Comparison – Drugs.com,     , https://www.drugs.com/compare/cardizem-cd-vs-cardizem-sr
82. Comparing Cardizem CD vs Cardizem LA – Drugs.com,     , https://www.drugs.com/compare/cardizem-cd-vs-cardizem-la
83. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation – American Heart Association Journals,     , https://www.ahajournals.org/doi/10.1161/CIR.0000000000001193?url_ver=Z39.88-2003&
84. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation,     , https://escholarship.org/content/qt4jb3s0pq/qt4jb3s0pq.pdf
85. Biovail Announces Closing of Acquisition of Worldwide Rights to Tetrabenazine,     , https://ir.bauschhealth.com/news-releases/archive/2009/22-06-2009
86. Ca antagonistic and non-specific effects of diltiazem on the rat phrenic nerve diaphragm preparation – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/2707302/
87. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease – American Heart Association Journals,     , https://www.ahajournals.org/doi/10.1161/CIR.0000000000001168
88. Cardizem La (diltiazem hydrochloride) – PrescriberPoint,     , https://prescriberpoint.com/therapies/cardizem-la-3e180dc
89. CARDIZEM LA (Diltiazem Hydrochloride) Extended Release Tablets – accessdata.fda.gov,     , https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021392lbl.pdf
90. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines – PubMed,     , https://pubmed.ncbi.nlm.nih.gov/38033089/